Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unity Biotechnology, Inc. - Common Stock (NQ:UBX)

0.6983 +0.0173 (+2.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Unity Biotechnology, Inc. - Common Stock

< Previous 1 2 Next >
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Reports Granting of New Employment Inducement Award
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Participate in Upcoming Investor Conferences
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Reports Granting of New Employment Inducement Award
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
Topline 16-week data expected in the fourth quarter of 2024 
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
From Unity Biotechnology, Inc.
Via GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET 
From Unity Biotechnology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.